Fact CheckerSign in

NCT06722092Not yet recruiting

VR and Scrip Training of PWA, Randomized Controlled Trial

Can Immersive Virtual Reality Magnify Treatment Outcomes of Script Training on Cantonese Speakers with Chronic Aphasia: a Randomized Controlled Trial

Source: ClinicalTrials.gov · Last updated 13 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The goal of this RCT is to investigate if computerized script training may promote functional communication and nonverbal cognitive functions of Cantonese-speaking PWA, and whether VR may further magnify the treatment outcomes. The main research questions are: 1. Can script training promote verbal functional communication of Cantonese-speaking PWA? 2. Can script training enhance nonverbal cognitive functions of Cantonese-speaking PWA? 3. Can VR magnify verbal and nonverbal treatment outcomes of script training of PWA?

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
105 (estimated)
First submitted
3 Dec 2024
Start date
Jun 2025
Primary completion date
Dec 2027
Lead sponsor
The Hong Kong Polytechnic University
Diseases
Stroke
NCT number
NCT06722092

What you commit to

  • Study type: Interventional
  • Planned participants: 105
  • From Jun 2025 to the primary completion date, Dec 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • concurrent participation in other aphasia treatment trials, and

Other

  • incompatibility with immersive VR exposure such as complains of nausea, headache, or other severe discomforts during trial use of a head-mounted device during screening.

Who the study is looking for

  • a stroke onset more than six months, with an Aphasia Quotient (AQ) below 96.4, as evaluated by the Cantonese version of Western Aphasia Battery (CAB; Yiu, 1992),
  • premorbid fluent Cantonese speakers,
  • aged between 30 and 80 years,
  • no reported progressive neurogenic disorders such as dementia or Parkinson's disease,
  • no motor speech disorders of moderate to severe level, and
  • normal or corrected-to-normal vision and hearing functions

Age in the registry: 30 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.